Bedtime Administration of NN2211, a Long-Acting GLP-1 Derivative, Substantially Reduces Fasting and Postprandial Glycemia
in Type 2 Diabetes
(Downloading may take up to 30 seconds. If the slide opens in your browser, select File -> Save As to save it.)
Click on image to view larger version.
Concentration profiles of NN2211 on the day of active treatment. The first 10 data points were obtained by sampling at fixed
time intervals; the last data point was obtained between 35 and 63 h post dosing. Gray lines indicate individual concentration
profiles; black line indicates mean ± SE.